GRTX Galera Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GRTX

Price (delayed)

$0.186

Market cap

$10.12M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.33

Enterprise value

-$6.89M

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera's lead ...

Highlights
The quick ratio has soared by 64% since the previous quarter and by 55% year-on-year
The company's EPS rose by 42% YoY and by 30% QoQ
GRTX's equity is down by 20% YoY and by 3.7% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://galeratx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of GRTX
Market
Shares outstanding
54.39M
Market cap
$10.12M
Enterprise value
-$6.89M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$47.67M
EBITDA
-$47.41M
Free cash flow
-$44.91M
Per share
EPS
-$1.33
Free cash flow per share
-$1.01
Book value per share
-$2.41
Revenue per share
$0
TBVPS
$0.52
Balance sheet
Total assets
$26.14M
Total liabilities
$157.33M
Debt
$1.25M
Equity
-$131.19M
Working capital
$16.67M
Liquidity
Debt to equity
-0.01
Current ratio
4.36
Quick ratio
3.68
Net debt/EBITDA
0.36
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-137.5%
Return on equity
N/A
Return on invested capital
-734.5%
Return on capital employed
-225%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GRTX stock price

How has the Galera Therapeutics stock price performed over time
Intraday
-2.11%
1 week
-2.11%
1 month
20.62%
1 year
-94.1%
YTD
27.92%
QTD
32.86%

Financial performance

How have Galera Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$49.26M
Net income
-$59.08M
Gross margin
N/A
Net margin
N/A
GRTX's net income is up by 15% from the previous quarter and by 5% YoY
The operating income is up by 14% since the previous quarter and by 3.8% year-on-year

Growth

What is Galera Therapeutics's growth rate over time

Valuation

What is Galera Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 42% YoY and by 30% QoQ
GRTX's equity is down by 20% YoY and by 3.7% QoQ

Efficiency

How efficient is Galera Therapeutics business performance
The ROIC has dropped by 59% since the previous quarter
The return on assets has declined by 25% year-on-year but it has grown by 6% since the previous quarter

Dividends

What is GRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GRTX.

Financial health

How did Galera Therapeutics financials performed over time
GRTX's total assets is 83% smaller than its total liabilities
The company's current ratio has surged by 77% QoQ and by 51% YoY
The quick ratio has soared by 64% since the previous quarter and by 55% year-on-year
The company's debt is 101% higher than its equity
GRTX's equity is down by 20% YoY and by 3.7% QoQ
The company's debt fell by 2.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.